135 related articles for article (PubMed ID: 20441964)
21. Novel design of peptides to reverse the anticoagulant activities of heparin and other glycosaminoglycans.
Schick BP; Gradowski JF; San Antonio JD; Martinez J
Thromb Haemost; 2001 Mar; 85(3):482-7. PubMed ID: 11307819
[TBL] [Abstract][Full Text] [Related]
22. Dermatan sulfate and LMW heparin enhance the anticoagulant action of activated protein C.
Fernández JA; Petäjä J; Griffin JH
Thromb Haemost; 1999 Nov; 82(5):1462-8. PubMed ID: 10595639
[TBL] [Abstract][Full Text] [Related]
23. Lack of anti-factor Xa assay standardization results in significant low molecular weight heparin (enoxaparin) dose variation in neonates and children.
Greene LA; Law C; Jung M; Walton S; Ignjatovic V; Monagle P; Raffini LJ
J Thromb Haemost; 2014 Sep; 12(9):1554-7. PubMed ID: 24943261
[TBL] [Abstract][Full Text] [Related]
24. Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous factor Xa and IIa formation and on thrombelastometry profiles.
Cvirn G; Wagner T; Juergens G; Koestenberger M
Blood Coagul Fibrinolysis; 2009 Jan; 20(1):71-7. PubMed ID: 20339323
[TBL] [Abstract][Full Text] [Related]
25. Monitoring Unfractionated Heparin (UFH) therapy: which Anti-Factor Xa assay is appropriate?
Ignjatovic V; Summerhayes R; Gan A; Than J; Chan A; Cochrane A; Bennett M; Horton S; Shann F; Lane G; Ross-Smith M; Monagle P
Thromb Res; 2007; 120(3):347-51. PubMed ID: 17118432
[TBL] [Abstract][Full Text] [Related]
26. Determination of low molecular weight heparin in clinical laboratory.
van Putten J; van de Ruit M; Beunis M; Hemker HC
Haemostasis; 1984; 14(2):205-10. PubMed ID: 6203817
[TBL] [Abstract][Full Text] [Related]
27. Eczematous plaques related to unfractionated and low-molecular-weight heparins: cross-reaction with danaparoid but not with desirudin.
Martin L; Machet L; Gironet N; Pouplard C; Gruel Y; Vaillant L
Contact Dermatitis; 2000 May; 42(5):295-6. PubMed ID: 10789857
[No Abstract] [Full Text] [Related]
28. Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides.
Ludwig RJ; Schindewolf M; Alban S; Kaufmann R; Lindhoff-Last E; Boehncke WH
Thromb Haemost; 2005 Dec; 94(6):1265-9. PubMed ID: 16411404
[TBL] [Abstract][Full Text] [Related]
29. Qualitative and quantitative analysis of heparin and low molecular weight heparins using size exclusion chromatography with multiple angle laser scattering/refractive index and inductively coupled plasma/mass spectrometry detectors.
Ouyang Y; Zeng Y; Yi L; Tang H; Li D; Linhardt RJ; Zhang Z
J Chromatogr A; 2017 Nov; 1522():56-61. PubMed ID: 28958760
[TBL] [Abstract][Full Text] [Related]
30. Combination of a two-step fluorescence assay and a two-step anti-Factor Xa assay for detection of heparin falsifications and protein in heparins.
Alban S; Lühn S; Schiemann S
Anal Bioanal Chem; 2011 Jan; 399(2):681-90. PubMed ID: 20953779
[TBL] [Abstract][Full Text] [Related]
31. Variability of plasma anti-Xa activities with different lots of enoxaparin.
Gosselin RC; King JH; Janatpour KA; Dager WE; Larkin EC; Owings JT
Ann Pharmacother; 2004 Apr; 38(4):563-8. PubMed ID: 14982983
[TBL] [Abstract][Full Text] [Related]
32. Determination of impurities in heparin by capillary electrophoresis using high molarity phosphate buffers.
Wielgos T; Havel K; Ivanova N; Weinberger R
J Pharm Biomed Anal; 2009 Feb; 49(2):319-26. PubMed ID: 19155153
[TBL] [Abstract][Full Text] [Related]
33. Can low molecular weight heparins and heparinoids be safely given to patients with heparin-induced thrombocytopenia syndrome?
Kikta MJ; Keller MP; Humphrey PW; Silver D
Surgery; 1993 Oct; 114(4):705-10. PubMed ID: 7692613
[TBL] [Abstract][Full Text] [Related]
34. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
[TBL] [Abstract][Full Text] [Related]
35. Quality assessment of unfractionated heparin using 1H nuclear magnetic resonance spectroscopy.
Beyer T; Diehl B; Randel G; Humpfer E; Schäfer H; Spraul M; Schollmayer C; Holzgrabe U
J Pharm Biomed Anal; 2008 Sep; 48(1):13-9. PubMed ID: 18678460
[TBL] [Abstract][Full Text] [Related]
36. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
[TBL] [Abstract][Full Text] [Related]
37. The effect of unfractionated heparin, enoxaparin, and danaparoid on lupus anticoagulant testing: Can activated carbon eliminate false-positive results?
De Kesel PMM; Devreese KMJ
Res Pract Thromb Haemost; 2020 Jan; 4(1):161-168. PubMed ID: 31989098
[TBL] [Abstract][Full Text] [Related]
38. A microfluidic anti-Factor Xa assay device for point of care monitoring of anticoagulation therapy.
Harris LF; Rainey P; Castro-López V; O'Donnell JS; Killard AJ
Analyst; 2013 Sep; 138(17):4769-76. PubMed ID: 23666610
[TBL] [Abstract][Full Text] [Related]
39. Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous formation of factor Xa and IIa and on thrombelastometry profiles in cord versus adult blood.
Cvirn G; Hoerl G; Tafeit E; Heinl N; Wodrig K; Wagner T; Koestenberger M; Juergens G
Neonatology; 2011; 100(1):23-31. PubMed ID: 21150227
[TBL] [Abstract][Full Text] [Related]
40. [Delayed hypersensitivity to heparins and heparinoids].
Nicolie B; Bonneau JC; Le Sellin J; Gay G; Leclere JM; Drouet M
Allerg Immunol (Paris); 2002 Feb; 34(2):47-50. PubMed ID: 11933754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
